TAK-448 in overweight/obese males with hypogonadotropic hypogonadism

Phase 2, open-label trial of TAK-448 in hypogonadotropic hypogonadism (HH) (5 arms), sponsored by Takeda. Primary endpoints: Percent Change From Baseline in Mean Area Under the Effect Curve From Time 0 to 72 Hours of Total Serum Testosterone, Percent Change From Baseline in Mean Area Under the Effect Curve From Time 0 to 72 Hours of Free Serum Testosterone and 2 more. Started Feb 2015; status: terminated.